News Search

25 Jul 2019 | Products

Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders

– Global Action Follows Notification of Updated Safety Information from the U.S. Food and Drug Administration (FDA) –

– Regulatory Bodies Around the World including the FDA and Therapeutic Goods Administration (TGA) Do Not Recommend Removal or Replacement of Textured Breast Implants in Asymptomatic Patients –

– Smooth and MICROCELL® Breast Implant Products are Not Impacted by this Recall –

DUBLIN, IRELAND JULY 24, 2019 Allergan plc (NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration (FDA).

The Therapeutic Goods Administration (TGA) has been informed of the global voluntary recall. A formal review into textured breast implants is currently underway by the TGA in Australia.

BIOCELL® saline-filled and silicone-filled textured breast implants and tissue expanders will no longer be distributed or sold in any market where they are currently available. Effective immediately, healthcare providers should no longer implant new BIOCELL® textured breast implants and tissue expanders and unused products should be returned to Allergan. Allergan will provide additional information to customers about how to return unused products.

Patient safety is a priority for Allergan. Patients are advised to speak with their plastic surgeon about the risks and benefits of their implant type should they have any concerns.

Importantly, regulatory bodies around the world including the TGA have not recommended removal or replacement of textured breast implants or tissue expanders in asymptomatic patients. 

This global recall does not affect Allergan’s NATRELLE® smooth or BRST MICROCELL® breast implant products.

The recalled products in Australia include:
Registration (ARTG) number Product
175422 Natrelle INSPIRA Truform 1 gel, Textured, Single Lumen
175425 Natrelle INSPIRA Truform 2 gel, Textured Single Lumen
175420 Natrelle Truform 1 gel, Textured, Single Lumen
171512 Natrelle Truform 3 gel, Textured Single Lumen
171475 Natrelle Soft Touch, Truform 2 gel, Textured, Single Lumen
171387 Natrelle Truform Dual gel, Textured Single Lumen
171388 Natrelle Saline-filled, Textured
169956 Natrelle Double Lumen Gel/Saline
175797 Natrelle Tissue Expanders - Skin expander
For full information relating to the global recall, please refer to Allergan’s global media release here.

Healthcare professionals and patients can contact Allergan’s Medical Information team for further information at or by phone at 1800 252 224.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Media Contacts
Cassandra Collier
Australia Media Enquiries
Tel: +61 488 118 256
Mark Marmur
Global Corporate Media Relations
Tel: +1 (862) 261 7558

Karina Calzadilla
Investor Relations
Tel: +1 862 261 7488